| Title |
Statin use and pancreatic cancer risk in two prospective cohort studies
|
|---|---|
| Published in |
Journal of Gastroenterology, January 2018
|
| DOI | 10.1007/s00535-018-1430-x |
| Pubmed ID | |
| Authors |
Tsuyoshi Hamada, Natalia Khalaf, Chen Yuan, Ana Babic, Vicente Morales-Oyarvide, Zhi Rong Qian, Jonathan Andrew Nowak, Kimmie Ng, Peter Kraft, Douglas Adam Rubinson, Meir Jonathan Stampfer, Edward Luciano Giovannucci, Charles Stewart Fuchs, Shuji Ogino, Brian Matthew Wolpin |
| Abstract |
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are common lipid-lowering agents and may reduce the risk of several cancer types including pancreatic cancer. However, the association between statin use and pancreatic cancer risk has not been fully evaluated in prospective studies. We studied the association between statin use and incident pancreatic cancer in 113,059 participants from the prospective Nurses' Health Study and Health Professionals Follow-up Study. Statin use was self-reported via study questionnaires and updated biennially. Hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of pancreatic cancer were estimated using multivariable Cox proportional hazards models with adjustment for potential confounders. In total, 583 participants developed incident pancreatic cancer during 1.4 million person-years of follow-up. No difference was identified in pancreatic cancer risk for regular versus non-regular statin users (multivariable-adjusted HR 0.98; 95% CI 0.82-1.16). There was no significant heterogeneity in the association of statin use with pancreatic cancer risk between the cohorts. Similarly, longer duration of regular statin use was not associated with decreased risk of pancreatic cancer (Ptrend = 0.65). The results remained similar when we examined statin use status at baseline or accounting for 4-year latency period. We observed no statistically significant effect modification for the association of statin use with pancreatic cancer risk by body mass index, smoking status, or diabetes mellitus status (all Pinteraction > 0.21). Regular statin use was not associated with pancreatic cancer risk in two large prospective cohort studies in the U.S. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 6 | 16% |
| Researcher | 4 | 11% |
| Student > Doctoral Student | 4 | 11% |
| Student > Master | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 6 | 16% |
| Unknown | 11 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 32% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Philosophy | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Other | 5 | 14% |
| Unknown | 12 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2018.
All research outputs
#15,489,831
of 23,018,998 outputs
Outputs from Journal of Gastroenterology
#749
of 1,101 outputs
Outputs of similar age
#269,985
of 441,020 outputs
Outputs of similar age from Journal of Gastroenterology
#8
of 16 outputs
Altmetric has tracked 23,018,998 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,101 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,020 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.